Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors

Walter K. Kraft, Thomas Jefferson UniversityFollow
John N van den Anker, George Washington University School of Medicine and Health SciencesFollow

Document Type

Article

Publication Date

10-1-2012

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in Pediatric Clinics of North America

Volume 59, Issue 5, October 2012, Pages 1147-1165.

The published version is available at DOI: 10.1016/j.pcl.2012.07.006. Copyright © Elsevier Inc.

Abstract

Opioid use in pregnant women has increased over the last decade. Following birth, infants with in utero exposure demonstrate signs and symptoms of withdrawal known as the neonatal abstinence syndrome (NAS). Infants express a spectrum of disease, with most requiring the administration of pharmacologic therapy to ensure proper growth and development. Treatment often involves prolonged hospitalization. There is a general lack of high-quality clinical trial data to guide optimal therapy, and significant heterogeneity in treatment approaches. Emerging trends in the treatment of infants with NAS include the use of sublingual buprenorphine, transition to outpatient therapy, and pharmacogenetic risk stratification.

Recommended Citation

Kraft, Walter K. and van den Anker, John N, "Pharmacologic management of the opioid neonatal abstinence syndrome." (2012). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 39.
https://jdc.jefferson.edu/petfp/39

PubMed ID

23036249